Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
Tacrolimus 0.1% probably leads to higher physician's assessment of global response of improvement, clear or… compared with corticosteroids (moderate certainty).
3 findings from 1 review
RR 3.09 [2.14, 4.45]
1 study · 371 participants
Moderate
RR 0.95 [0.78, 1.16]
1 study · 377 participants
Low
RR 1.32 [1.17, 1.49]
1 study · 972 participants
Moderate
Adverse effects ‐ burning · people with atopic dermatitis
Tacrolimus 0.1% probably leads to higher adverse effects: burning ‐ tacrolimus 0.1% versus hydrocortisone… compared with corticosteroids (moderate certainty).
3 findings from 1 review
RR 2.91 [1.6, 5.28]
1 study · 371 participants
Moderate
RR 4.59 [3.1, 6.78]
1 study · 377 participants
Moderate
RR 3.79 [2.99, 4.81]
1 study · 972 participants
Moderate
Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
Tacrolimus 0.03% probably leads to higher physician's assessment of global response of improvement, clear or… compared with corticosteroids (moderate certainty).
4 findings from 1 review
RR 2.05 [1.36, 3.08]
1 study · 411 participants
Moderate
RR 2.58 [1.96, 3.38]
2 studies · 790 participants
Moderate
RR 0.45 [0.13, 1.57]
2 studies · 409 participants
Very low
Show 1 more finding
Adverse effects ‐ burning · people with atopic dermatitis
1 finding from 1 review
Participant's self‐assessment of global response of improvement: tacrolimus 0.03% 2x/day versus hydrocortisone acetate 1% 2x/day · people with atopic dermatitis
Tacrolimus 0.03% probably leads to higher participant's self‐assessment of global response of improvement:… compared with corticosteroids (moderate certainty).
1 finding from 1 review
Physician's assessment of global response of improvement · people with atopic dermatitis
Tacrolimus 0.03% leads to lower physician's assessment of global response of improvement, clear or… compared with tacrolimus 0.1% (high certainty).
1 finding from 1 review
Adverse effects · people with atopic dermatitis
Tacrolimus 0.03% showed no clear difference in adverse effects compared with tacrolimus 0.1% (moderate certainty).
1 finding from 1 review
Adverse effects · people with atopic dermatitis
It is very uncertain whether tacrolimus 0.1% changes adverse effects compared with ciclosporin (very low certainty).
1 finding from 1 review
Participant's self‐assessment of global response of improvement · people with atopic dermatitis
Tacrolimus 0.1% may leads to higher participant's self‐assessment of global response of improvement compared with corticosteroids (low certainty).
1 finding from 1 review
Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
Tacrolimus 0.1% probably leads to higher physician's assessment of global response of improvement, clear or… compared with pimecrolimus 1% (moderate certainty).
1 finding from 1 review
Adverse effects ‐ 6 weeks · people with atopic dermatitis
It is very uncertain whether tacrolimus 0.1% changes adverse effects ‐ 6 weeks compared with pimecrolimus 1% (very low certainty).
1 finding from 1 review
Physician's assessment of global response of improvement · people with atopic dermatitis
Tacrolimus 0.03% may leads to higher physician's assessment of global response of improvement compared with pimecrolimus 1% (low certainty).
1 finding from 1 review
Adverse effects ‐ application site reaction · people with atopic dermatitis
Tacrolimus 0.03% showed no clear difference in adverse effects ‐ application site reaction compared with pimecrolimus 1% (low certainty).
1 finding from 1 review
Adverse effects ‐ burning · people with atopic dermatitis
Tacrolimus 0.03% showed no clear difference in adverse effects ‐ burning compared with pimecrolimus 1% (low certainty).
1 finding from 1 review
Adverse effects ‐ itching · people with atopic dermatitis
Tacrolimus 0.03% showed no clear difference in adverse effects ‐ itching compared with pimecrolimus 1% (low certainty).
1 finding from 1 review
Adverse effects ‐ erythema · people with atopic dermatitis
Tacrolimus 0.03% showed no clear difference in adverse effects ‐ erythema compared with pimecrolimus 1% (low certainty).
1 finding from 1 review
Clearing or excellent improvement · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
At least 50% reduction in erythema · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life measure · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Relapse · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review